Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to $1.7 million.

  • Macrogenics' Change in Accured Expenses fell 809.1% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 million, marking a year-over-year decrease of 9796.7%. This contributed to the annual value of $5.0 million for FY2024, which is 20373.21% up from last year.
  • As of Q3 2025, Macrogenics' Change in Accured Expenses stood at $1.7 million, which was down 809.1% from -$8.9 million recorded in Q2 2025.
  • In the past 5 years, Macrogenics' Change in Accured Expenses registered a high of $6.3 million during Q4 2022, and its lowest value of -$11.9 million during Q1 2022.
  • Its 5-year average for Change in Accured Expenses is -$577789.5, with a median of $1.3 million in 2025.
  • As far as peak fluctuations go, Macrogenics' Change in Accured Expenses tumbled by 75172.23% in 2022, and later skyrocketed by 330551.72% in 2024.
  • Macrogenics' Change in Accured Expenses (Quarter) stood at -$8.4 million in 2021, then surged by 174.95% to $6.3 million in 2022, then plummeted by 122.93% to -$1.4 million in 2023, then skyrocketed by 403.48% to $4.4 million in 2024, then crashed by 60.09% to $1.7 million in 2025.
  • Its Change in Accured Expenses was $1.7 million in Q3 2025, compared to -$8.9 million in Q2 2025 and $1.3 million in Q1 2025.